Study of Profound's prostate cancer device gets green light

09/19/2013 | MassDevice.com (Boston)

The FDA has granted Profound Medical investigational device exemption approval to conduct a clinical study of its device that uses real-time MRI guidance and thermal ultrasound to treat patients with localized prostate cancer. The Canadian company plans to start patient enrollment in the trial in late 2013.

View Full Article in:

MassDevice.com (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA